Aug 4, 2020 Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
Jul 21, 2020 Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS
Jun 11, 2020 Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
May 26, 2020 Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
